Clinical trials: the full study lifecycle.

Clinical trials run on the bioanalytical spine for PK and biomarker measurement and share ICH-GCP discipline with bioequivalence. Governance gates everything. Click a node to open that space.

The phase architecture has held since the 1960s. What changes in the AI-native era is not the phases — it's the operational layer underneath them. Recruitment, monitoring, data capture, signal detection: each of these is being reshaped while the phase logic remains.

The operational arc of any clinical study is six stages. Each produces specific deliverables. Each has named regulator-facing artefacts. Each is where AI is reshaping the work most visibly.

Three shifts are reshaping clinical operations through 2026 and into 2030. Each is regulator-acknowledged. Each requires the immunity layer iFeed builds.

Nine pillars define the operational shape of a defensible GCP programme — from sponsor oversight through trial master file. Below: a quick-reference grid · then a colour-coded drilldown comparing ICH E6(R3) · FDA · EMA · MHRA · PMDA on each. Sponsor oversight (★), decentralised trial elements (★), and electronic systems (★) are where divergence runs deepest in 2026.

Modern clinical trial regulation is the residue of scandal answered by ethics answered by codification. Each line in the timeline below is a moment where the conduct of research on human beings shifted from investigator conscience to written, enforceable rule.

The history is not a smooth curve. It is a sequence of eras, each defined by the question the field was answering. The current era is decentralisation overlaid with AI augmentation; the next is what comes after that.

The 2026 picture is a five-regulator divergence matrix overlaid with a partially harmonised E6(R3) substrate. The shifts below are operational, not theoretical — they affect dossier preparation today.

Forward views below are calibrated by confidence: high means trend is operational and trajectory clear; medium means direction is plausible but politically or technically uncertain; low means the substrate exists but the regulatory and reimbursement infrastructure does not.

The honest map of AI in trial conduct sorts use cases by what they actually replace and how mature the regulator's posture is. Some are production (deployed at sponsors and inspection-acceptable), some inspection-acceptable with caveats, some still piloting. One is regulator-flagged as a high-risk finding.

The lifecycle below is the operational pipeline that sits beneath the four-phase architecture. Each step has a regulator-facing artefact; each is a place where studies most often slip schedule or trigger inspection findings.

Trials are not run for their own sake. Each design exists to answer a specific regulatory or commercial question. The use cases below cover the modern field; sponsors typically run several in parallel across a single asset's lifecycle.

The clinical trial economy is dense. The map below groups the named institutions sponsors and regulators interact with most often. None of these are endorsements; the list is the operational reality.

Every clinical trial is a negotiation between unequal parties with overlapping interests. The stake-table below names each party and the lever it actually pulls. The map matters because most operational disputes (timeline, scope, deviation handling) trace back to a misread leverage relationship.